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We read with interest the description
by El-Hamamsy and colleagues1 of
a young woman who received a homo-
vital homograft aortic root replacement
that remains in situ with preserved
function 32 years later. The description
of this patient echoes our experience
with noncryopreserved aortic homo-
grafts. In the mid to late 1970s at
Southampton General Hospital, we
too favored homografts for aortic valve
replacement, especially in young
women. Our preferencewas antibiotic-
sterilized homograft valves that re-
mained in storage refrigerated at 4C.
The majority of homografts were im-
planted within 8 weeks, but storage ex-
tended to as long as 17 weeks. For
isolated valvular pathology, implanta-
tion was ordinarily subcoronary using
the techniques described by Ross2 and
Barratt-Boyes.3 Subcoronary implanta-
tion, although technically challenging,
lends itself to a significantly less haz-
ardous reoperation than root or mini-
root replacement.
In our experience, the durability of
subcoronary antibiotic-sterilized re-
frigerated homografts has exceededThe Journalthat of tissue prostheses or cryopre-
served allografts, particularly in chil-
dren and young adults. Among our
cohort of 200 consecutive young adults
receiving subcoronary homografts, 7
were alive with their original homo-
graft in situ between 25 and 29.8 years
later at the time of our last report in
2007.4 Since the time of our last report,
1 of these 7 patients underwent reoper-
ation 32.3 years after the original valve
implantation. The other 6 patients re-
main alive and free from reoperation
(maximum of 30 years with the latest
echocardiogram reporting mild regur-
gitation, peak instantaneous gradient
of 27 mm Hg, and normal ventricular
function and dimensions).Overall free-
dom from reoperation in survivors was
approximately 40% at 20 years.
Together with our experience, the
case reported by the London group1
adds credence to the suggestion that
noncryopreserved allograft prostheses
may outperform present-day cryopre-
served allografts (and indeed perhaps
modern tissue bioprostheses). Limited
availability of allografts provided the
impetus for the widespread introduc-
tion of cryopreservationwith its poten-
tial for longer (perhaps indefinite)
storage. Nevertheless, limited avail-
ability relates primarily to logistics ofof Thoracic and Cardiovascular Surgeprocurement and consent, which may
be mutable hurdles. Perhaps it is time
to reexamine the biologic properties
of noncryopreserved allograft im-
plants with a view to addressing the lo-
gistics of donor acquisition and valve
procurement if necessary.
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